Q32 Bio Inc. (QTTB) Investor Relations Documents

Q32 Bio Inc. (QTTB) investor relations documents from the company's IR site: 2 presentations, 13 press releases; latest deck 2026-08-18. Read in-app with summaries. First-party data.

Corporate Presentation: Q32 Bio's August 2026 presentation details bempikibart, an IL-7/TSLP inhibitor for Alopecia Areata, with positive Phase 2a data and plans for a registration-directed program.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-18PresentationCorporate Presentation
2026-08-05Press releaseQ32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-07-14Press releaseQ32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
2026-07-13Press releaseQ32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2026-07-13Press releaseQ32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopeci
2026-07-12PresentationView Presentation
2026-07-10Press releaseQ32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on J
2026-05-27Press releaseQ32 Bio Announces $55 Million Private Placement Financing
2026-05-05Press releaseQ32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-04-08Press releaseQ32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference
2026-03-10Press releaseQ32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
2026-02-18Press releaseQ32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
DocumentQ32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
DocumentQ32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
DocumentQ32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
2025-03-11Press releaseQ32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
2024-12-10Press releaseQ32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program
2024-05-09Press releaseQ32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

QTTB overview · QTTB earnings · QTTB financials · QTTB KPIs · QTTB ownership · QTTB peers · QTTB filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.